# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0187 |
| Population Package | PP-0187 |
| Title | NGS Biomarker Testing |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD — READY FOR INTEGRATION |

---

# Layer 1 — Content QA

| Criterion | Result |
|---|---|
| Single educational question | PASS |
| Scope respected | PASS |
| Complete coverage of locked scope | PASS |
| Internal consistency | PASS |
| Logical organization | PASS |
| Clinical knowledge blocks complete | PASS |
| Patient-facing interpretation included | PASS |
| Common misconceptions addressed | PASS |
| Knowledge Graph complete | PASS |
| No unnecessary compacting | PASS |
| Full-depth requirement satisfied | PASS |
| No material from delegated packages improperly absorbed | PASS |

### Content QA Notes

The package preserves the approved PP-0187 scope as a platform-level NGS package. It does not collapse NGS into a simple definition and does not expand into a technical sequencing manual, genomic-report interpretation package, or treatment algorithm.

---

# Layer 2 — Clinical QA

| Criterion | Result |
|---|---|
| Scientifically coherent | PASS |
| Consistent with supplied NCCN gastric-cancer source | PASS |
| NGS described as a testing platform | PASS |
| Distinction between NGS and individual biomarkers maintained | PASS |
| IHC/ISH/targeted PCR relationship preserved | PASS |
| Validated NGS concept preserved | PASS |
| Sufficient tumor tissue concept preserved | PASS |
| Selected blood-based NGS context accurately bounded | PASS |
| TMB/MSI relationship accurately bounded | PASS |
| HER2/FGFR2 examples do not replace dedicated packages | PASS |
| No unsupported universal NGS mandate | PASS |
| No unsupported universal panel recommendation | PASS |
| No unsupported analytical thresholds | PASS |
| No individualized treatment recommendation | PASS |
| No unsafe clinical advice | PASS |

### Clinical QA Notes

The supplied NCCN v2.2026 material directly supports NGS as a broader molecular-testing approach, including simultaneous assessment of multiple mutations and molecular events, validated NGS in selected contexts, and selected blood-based comprehensive genomic profiling/MGPT when tissue is limited or biopsy is not feasible in appropriate advanced/metastatic disease.

The package intentionally avoids converting these statements into universal testing rules.

---

# Layer 3 — Educational QA

| Criterion | Result |
|---|---|
| Plain-language explanation | PASS |
| Patient-friendly organization | PASS |
| Technical terms explained conceptually | PASS |
| Learning objectives satisfied | PASS |
| Positive/negative results explained appropriately | PASS |
| “No actionable alteration” distinguished from “no mutation” | PASS |
| Common misconceptions addressed | PASS |
| NGS not portrayed as treatment decision-maker | PASS |
| NGS not portrayed as biopsy/pathology replacement | PASS |
| Somatic versus germline distinction included | PASS |
| Appropriate uncertainty language | PASS |

### Educational QA Notes

The package deliberately uses a layered explanation:

**Clinical question → specimen → validated testing → NGS/multigene profiling → molecular findings → interpretation → clinical relevance**

This provides enough depth for patient understanding without entering technical laboratory or specialist interpretation domains.

---

# Layer 4 — Governance QA

| Criterion | Result |
|---|---|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Primary Evidence Package completed | PASS |
| QA Report completed | PASS |
| Evidence traceability included | PASS |
| Scope matches locked Decision Batch | PASS |
| Boundary included | PASS |
| Boundary uses four-part format | PASS |
| Knowledge Graph included | PASS |
| Versioning complete | PASS |
| Repository naming compliant | PASS |
| Gold structure preserved | PASS |
| ZIP package contains exactly four required artifacts | PASS |
| ZIP package title includes PP number and title | PASS |

---

# Clinical Safety Review

| Item | Result |
|---|---|
| No individualized treatment recommendation | PASS |
| No universal NGS mandate | PASS |
| No unsupported biomarker threshold | PASS |
| No unsupported assay recommendation | PASS |
| No false implication that NGS detects every alteration | PASS |
| No implication that negative NGS excludes cancer/genomic alteration | PASS |
| No implication that NGS replaces pathology or staging | PASS |
| No implication that tumor NGS equals germline testing | PASS |
| No unsupported drug-selection statement | PASS |
| Appropriate referral to downstream packages | PASS |

---

# Evidence Traceability Review

## High-confidence direct claims

The following claims are directly grounded in the supplied NCCN v2.2026 source:

- NGS can assess numerous mutations simultaneously.
- NGS can assess other molecular events including amplification and deletions.
- NGS can assess TMB and MSI.
- IHC/ISH/targeted gene PCR are preferred initial approaches to biomarker assessment.
- Validated NGS through a CLIA-approved laboratory may be considered later in the clinical course when sufficient tumor tissue is available.
- Selected blood-based NGS-based comprehensive genomic profiling/MGPT may be considered when tissue is limited or traditional biopsy cannot be performed in appropriate advanced/metastatic disease contexts.

## Interpretive educational claims

The package also makes conceptual statements such as:

- NGS is a testing platform rather than a biomarker.
- A negative test is limited by the assay's scope.
- A molecular finding does not automatically determine treatment.

These are framed as educational guardrails rather than disease-specific treatment claims.

---

# Boundary QA

## Core

NGS as a clinical molecular-testing platform; broader genomic/multigene profiling; molecular-event classes; clinical contexts for consideration; specimen adequacy; validated testing; conceptual result interpretation and limitations.

## Supporting

Precision oncology, somatic-versus-germline distinction, selected blood-based genomic testing, molecular evolution at a high level, and representative biomarker relationships.

## Explicitly Excluded

Technical sequencing workflow, bioinformatics, variant calling, variant interpretation, genomic-report interpretation, germline counseling, commercial assay comparison, universal NGS mandates, individualized treatment, detailed ctDNA monitoring, MRD and recurrence algorithms.

## Delegated-to PP

PP-0106, PP-0112, PP-0181–PP-0186, PP-0188, PP-0189, PP-0190, PP-0191 and downstream treatment-specific packages.

**Boundary QA: PASS**

---

# Adjacent Package Overlap QA

| Adjacent PP | Overlap Risk | Resolution | Result |
|---|---|---|---|
| PP-0181 HER2 Testing | NGS may detect HER2 amplification | PP-0181 owns HER2-specific testing; PP-0187 owns platform relationship | PASS |
| PP-0182 MSI/MMR | NGS may assess MSI | PP-0182 owns MSI/MMR interpretation | PASS |
| PP-0183 PD-L1 | Biomarker-testing overlap | PD-L1 remains IHC-specific package | PASS |
| PP-0184 CLDN18.2 | Biomarker-testing overlap | CLDN18.2 remains dedicated IHC package | PASS |
| PP-0185 TMB | NGS can provide TMB | PP-0185 owns TMB definition/interpretation | PASS |
| PP-0186 FGFR2 | NGS can detect genomic FGFR2 findings | PP-0186 owns FGFR2-specific testing | PASS |
| PP-0112 ctDNA | Blood-based NGS overlap | PP-0112 owns ctDNA biology/monitoring; PP-0187 owns NGS platform | PASS |
| PP-0188 Molecular Subtypes | NGS data may contribute to classification | PP-0188 owns subtype definitions | PASS |
| PP-0189 Genomic Report | NGS generates report | PP-0189 owns report interpretation | PASS |
| PP-0190 Targeted Therapy Biomarker Testing | NGS may identify relevant findings | PP-0190 owns therapy-linked testing decisions | PASS |
| PP-0191 Immunotherapy Biomarker Testing | NGS may provide MSI/TMB | PP-0191 owns immunotherapy biomarker application | PASS |

---

# Atomic Knowledge Principle

**PASS**

PP-0187 remains one coherent educational unit:

> **NGS Biomarker Testing**

It does not absorb:

- all individual biomarkers;
- all genomic interpretation;
- all liquid biopsy;
- all molecular classification;
- all targeted therapy;
- all immunotherapy.

---

# Depth Compliance Review

The project has a mandatory full-depth rule for both Discussion and final Gold artifacts.

This package was produced using the stored Gold artifact structure and the approved Discussion depth reference as the minimum depth baseline.

The package:

- preserves all required Gold sections;
- provides detailed knowledge blocks rather than compact bullet-only summaries;
- includes clinical context and limitations;
- includes boundary and overlap analysis;
- includes evidence classification and evidence gaps;
- includes patient-facing misconceptions and key messages;
- includes Knowledge Graph and delegation;
- does not shorten the package merely for concision.

**Depth compliance: PASS — FULL DEPTH.**

---

# Repository Readiness

| Requirement | Result |
|---|---|
| Four required markdown artifacts | PASS |
| Standard filenames | PASS |
| PP identifier consistent | PASS |
| Title consistent across artifacts | PASS |
| Version consistent | PASS |
| Status consistent | PASS |
| Evidence traceability | PASS |
| Boundary consistency | PASS |
| Knowledge Graph consistency | PASS |
| QA complete | PASS |

---

# Final Quality Decision

# **PASS**

PP-0187 satisfies the locked **FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.0** and the approved PP-0187 Decision Batch.

The package is:

> **GOLD — FULL DEPTH — READY FOR INTEGRATION**

---

# Reviewer Notes

PP-0187 occupies a clean platform-level position in the gastric-cancer molecular knowledge graph:

**Biomarker Testing**
↓
**Molecular Testing**
↓
**NGS / Multigene Profiling**
↓
**Molecular Findings**
↓
**Genomic Report Interpretation**
↓
**Biomarker-Guided Treatment Assessment**

The package deliberately preserves the ownership boundary between the NGS platform and downstream biomarker-specific, variant-interpretation, report-reading, and treatment packages.

---

# Final QA Status

**PASS — GOLD — READY FOR INTEGRATION**
